Mizuho raises BridgeBio Pharma stock price target to $110 on Attruby

Mizuho raised its BridgeBio Pharma (BBIO) price target to $110 from $96 (Outperform) as the stock trades at $76.07, projecting strong upside alongside a revised peak Attruby sales estimate of ~$4.0B vs ~$3.4B previously, after CARDIO-TTRansform trial failures. BBIO also reported Q2’26 revenue of $243.7M vs $221M consensus, with U.S. Attruby net product revenue at $222.4M, driving multiple firms to lift targets (e.g., Canaccord to $106; Piper Sandler to $115). Separately, KKR Genetic Disorder L.P. announced a secondary offering of 5M BBIO shares (company receives no proceeds), while the article notes Wall Street softness tied to surging oil prices but expects gains for August.

Analysis

BBIO is transitioning from a hype-driven biotech to a real commercial asset, which changes the valuation framework: the market will start paying for launch durability and margin conversion rather than just pipeline optionality. The near-term winner is likely the equity story itself, but the sponsor secondary is an important technical overhang; when a large holder sells into strength, upside often pauses until the new supply is absorbed. That means the stock can still re-rate over 1-3 months if sell-side numbers keep moving higher, but the first move may be choppy rather than linear.

The competitive read-through is more important than the headline. The setback for IONS/AZN removes a credible future threat, which should extend BBIO’s runway and reduce the probability of an early price-war in the ATTR franchise; that supports share capture and pricing power for at least the next 2-4 quarters. Longer term, the real question is whether BBIO can turn early demand into a repeatable prescribing habit without payer friction or slowdown in treatment-naive starts. If the next earnings print shows deceleration or gross-to-net pressure, the market will likely compress the multiple quickly because the story has moved from science risk to execution risk.

Contrarian view: consensus may be underestimating how much of the first leg is already in the price. The Street is extrapolating an unusually clean launch curve and a more benign competitive backdrop; both are fragile. A move above recent highs is plausible, but unless the company proves sustained script velocity into the Commercial Day and post-secondary period, the stock is vulnerable to a "show-me" reset. For GILD, the read-through is milder: investors may favor large-cap biotech with visible execution, but this is more a factor rotation tailwind than a direct earnings impact.

Key Decisions for Investors

• Long BBIO on post-secondary weakness, but only after supply clears; target a 15-25% move over 1-3 months if launch metrics continue to inflect. Falsifier: two consecutive months of decelerating new starts or any guidance/call commentary pointing to payer friction.
• Pair trade: long BBIO / short IONS for 1-3 months to express the widening competitive moat in ATTR-related prescribing. Risk: the short leg can squeeze if the market decides the failed program is already fully discounted.
• Avoid chasing BBIO into the next 1-2 sessions if volume spikes on the offering; wait for stabilization above the secondary-clearing level before adding risk. If it cannot hold that level for a week, the market is likely telling you the growth story is still too dependent on momentum flows.
• For longer-duration biotech exposure, overweight GILD versus smaller, launch-dependent names as a cleaner way to own execution quality; this is a 6-12 month relative-value idea, not a catalyst trade. Falsifier: if BBIO continues to reaccelerate while GILD launch execution stalls.
• Set an alert for BBIO into the October Commercial Day: if management raises peak-share or long-range revenue framing without any offset on pricing/competition, the stock can see a second rerating leg; if not, expect a multiple reset.